Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ananda PharmaSTU:1FX Receivables Turnover is 0.06 as of Jul. 2025. The stock has 5 warning signs investors should review. Among 951 Drug Manufacturers companies, Ananda Pharma ranks worse than 100% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ananda Pharma's Revenue for the
six
months ended in Jul. 2025 was €0.01 Mil. Ananda Pharma's average Accounts Receivable for the
six
months ended in Jul. 2025 was €0.11 Mil.
Hence, Ananda Pharma's Receivables Turnover for the
six
months ended in Jul. 2025 was 0.06.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Ananda Pharma Receivables Turnover Related Terms
Ananda Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Ananda Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1FX vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ananda Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ananda Pharma Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ananda Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Ananda Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ananda Pharma (STU:1FX) has a Receivables Turnover of 0.06 as of Jul. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ananda Pharma and its competitors. According to the industry distribution chart, Ananda Pharma ranks #951 out of 951 companies in the Drug Manufacturers industry.
Is Ananda Pharma's Receivables Turnover too high?
Ananda Pharma's current Receivables Turnover is 0.06. The Drug Manufacturers industry median Receivables Turnover is 5.07. Ananda Pharma's value of 0.06 is 98.8% below this industry median. Based on the distribution chart, Ananda Pharma ranks #951 out of 951 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Ananda Pharma's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ananda Pharma ranks #951 out of 951 companies for Receivables Turnover. This places Ananda Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.07. Ananda Pharma's value of 0.06 is 98.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ananda Pharma's current Receivables Turnover of 0.06 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ananda Pharma and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ananda Pharma's current Receivables Turnover is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ananda Pharma stock overvalued right now?
Ananda Pharma (STU:1FX) has a current Receivables Turnover of 0.06. The current Receivables Turnover is 0.06 and 98.8% below the Drug Manufacturers industry median of 5.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Ananda Pharma (STU:1FX), the current Receivables Turnover is 0.06 as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ananda Pharma PLC is a UK-based biopharmaceutical company developing regulatory-approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy-induced peripheral neuropathy (funded by NIHR).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1FX has been successfully added to your 
